Hanall Biopharma - Asset Resilience Ratio
Hanall Biopharma (009420) has an Asset Resilience Ratio of 3.91% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hanall Biopharma (009420) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Hanall Biopharma's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 009420 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Hanall Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Hanall Biopharma (009420) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.32 Billion | 3.91% |
| Total Liquid Assets | ₩8.32 Billion | 3.91% |
Asset Resilience Insights
- Limited Liquidity: Hanall Biopharma maintains only 3.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanall Biopharma Industry Peers by Asset Resilience Ratio
Compare Hanall Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Hanall Biopharma (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Hanall Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.91% | ₩8.32 Billion ≈ $5.64 Million |
₩212.88 Billion ≈ $144.27 Million |
-5.59pp |
| 2023-12-31 | 9.50% | ₩22.77 Billion ≈ $15.43 Million |
₩239.75 Billion ≈ $162.47 Million |
-7.88pp |
| 2022-12-31 | 17.38% | ₩37.09 Billion ≈ $25.14 Million |
₩213.45 Billion ≈ $144.65 Million |
-16.77pp |
| 2021-12-31 | 34.15% | ₩67.78 Billion ≈ $45.93 Million |
₩198.48 Billion ≈ $134.51 Million |
-5.15pp |
| 2020-12-31 | 39.30% | ₩86.51 Billion ≈ $58.62 Million |
₩220.13 Billion ≈ $149.18 Million |
-7.37pp |
| 2019-12-31 | 46.67% | ₩89.31 Billion ≈ $60.53 Million |
₩191.38 Billion ≈ $129.70 Million |
+5.59pp |
| 2018-12-31 | 41.08% | ₩66.67 Billion ≈ $45.18 Million |
₩162.30 Billion ≈ $109.99 Million |
+9.26pp |
| 2017-12-31 | 31.82% | ₩53.67 Billion ≈ $36.37 Million |
₩168.70 Billion ≈ $114.32 Million |
-4.62pp |
| 2016-12-31 | 36.43% | ₩45.44 Billion ≈ $30.80 Million |
₩124.73 Billion ≈ $84.53 Million |
+3.16pp |
| 2015-12-31 | 33.28% | ₩38.98 Billion ≈ $26.41 Million |
₩117.13 Billion ≈ $79.37 Million |
+26.11pp |
| 2014-12-31 | 7.17% | ₩6.25 Billion ≈ $4.23 Million |
₩87.17 Billion ≈ $59.07 Million |
+0.16pp |
| 2013-12-31 | 7.01% | ₩6.86 Billion ≈ $4.65 Million |
₩97.85 Billion ≈ $66.31 Million |
-12.27pp |
| 2012-12-31 | 19.27% | ₩23.95 Billion ≈ $16.23 Million |
₩124.27 Billion ≈ $84.22 Million |
+11.34pp |
| 2011-12-31 | 7.93% | ₩8.36 Billion ≈ $5.67 Million |
₩105.46 Billion ≈ $71.47 Million |
-- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more